Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ibotta, Inc. due to allegations of misleading statements and failure to disclose risks related to its contract with Kroger, which may have led to significant investor losses [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Ibotta to contact them directly to discuss their legal options [1]. - There is a deadline of June 16, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Ibotta [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Financial Performance and Stock Impact - Ibotta conducted its IPO on April 13, 2024, offering 6.6 million shares at a price of $88.00 per share [5]. - On August 13, 2024, Ibotta reported a net loss of $34.0 million for Q2 2024, with operating expenses more than doubling year-over-year, leading to a 26% drop in stock price to $42.66 [6]. - Following a disappointing Q4 earnings report on February 26, 2025, Ibotta's stock plummeted by 46% to close at $34.01 [7]. Group 3: Contractual Risks - The complaint against Ibotta alleges that the company failed to disclose the at-will nature of its contract with Kroger, which could be terminated without warning, posing a significant risk to investors [4]. - Ibotta provided vague warnings about maintaining client relationships without addressing the specific risk of losing a major client like Kroger [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Compass To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Compass stock or options between May 1, 2024 and May 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]/PRNewswire/ -- Faruqi & ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) between May 2, 2024, to May 6, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Cesar Torres v. Vestis Corporation, et al. (Case No. 1:25-cv-04844) has been commenced in the United States District Court for the Southern District of ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Compass To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Compass stock or options between May 1, 2024 and May 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]NEW YORK, June 6, 2025 /PRNewswire/ -- Faruqi ...

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misrepresenting its capital allocation priorities and significantly reducing its quarterly dividend [1][6]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey [1]. - Investors who acquired Organon shares during the class period (October 31, 2024 – April 30, 2025) are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025 [1][3][6]. Group 2: Allegations Against Organon - Organon is accused of concealing material information regarding its capital allocation priorities, particularly about its quarterly dividend [6]. - The company allegedly misrepresented its commitment to dividends while internally prioritizing debt reduction [6]. - Following the acquisition of Dermavant Sciences Ltd., Organon reduced its quarterly dividend by over 70% [6].

Core Viewpoint - A securities class action lawsuit has been filed against Krispy Kreme, alleging false or misleading statements regarding its partnership with McDonald's and the subsequent decline in product demand [1][6]. Allegations - Krispy Kreme allegedly made false or misleading statements and/or failed to disclose a significant decline in demand for products at McDonald's after the initial marketing launch [6]. - This decline led to lower average sales per location [6]. - The partnership with McDonald's was reportedly not profitable [6]. - These issues posed risks to the continuation of the partnership [6]. - As a result, Krispy Kreme would pause expanding to new McDonald's locations [6]. Legal Context - The law firm Wolf Haldenstein, with over 125 years of experience in securities litigation, is representing the investors affected by these alleged misrepresentations [4]. - Investors who purchased Krispy Kreme securities during the specified class period have until July 15, 2025, to request to be appointed as Lead Plaintiff [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Civitas Resources, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's oil production and financial condition [3][5]. Group 1: Allegations Against Civitas - The complaint alleges that Civitas was likely to significantly reduce its oil production in 2025 due to declines following a production peak in the DJ Basin in Q4 2024 and a low TIL count at the end of 2024 [5]. - It is claimed that increasing oil production would necessitate acquiring additional acreage and development locations, leading to significant debt and asset sales to offset acquisition costs [5]. - The company's financial condition reportedly required disruptive cost-reduction measures, including a significant workforce reduction [5]. - As a result, Civitas's business and financial prospects, as well as operational capabilities, were overstated, making public statements materially false and misleading [5]. Group 2: Financial Performance and Market Reaction - On February 24, 2025, Civitas reported its Q4 and full-year financial results, missing consensus estimates in revenue and non-GAAP EPS, and announced a 10% workforce reduction [6]. - Following this news, Civitas's stock price fell by $8.95, or 18.2%, closing at $40.35 per share on February 25, 2025, resulting in investor losses [7]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses in Civitas are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of July 1, 2025, to seek the role of lead plaintiff in the class action [3][9]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ibotta, Inc. due to allegations of misleading statements and failure to disclose risks related to its contract with Kroger, which may have led to significant investor losses [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Ibotta to contact them to discuss legal options, particularly in light of a federal securities class action filed against the company [1][2]. - The deadline for investors to seek the role of lead plaintiff in the class action is June 16, 2025 [2]. Group 2: Financial Performance and Stock Impact - Ibotta conducted its IPO on April 13, 2024, offering 6.6 million shares at $88.00 each [5]. - The company reported a net loss of $34.0 million for Q2 2024, with operating expenses more than doubling year-over-year, leading to a 26% drop in stock price to $42.66 on August 14, 2024 [6]. - On February 26, 2025, Ibotta's stock fell 46% to $34.01 after reporting Q4 earnings that missed expectations and provided disappointing guidance for Q1 2025 [7]. Group 3: Contractual Risks - The complaint against Ibotta alleges that the company did not disclose the at-will nature of its contract with Kroger, which allowed Kroger to terminate the agreement without notice, posing a significant risk to investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Napco Security Technologies, Inc. due to allegations of false and misleading statements regarding the company's growth and hardware division performance [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the June 24, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Napco [2]. - The complaint alleges that Napco and its executives violated federal securities laws by failing to disclose material information about the company's expected growth and hardware division strength [4]. Group 2: Financial Performance and Stock Impact - On February 3, 2025, Napco reported a significant reduction in hardware sales, attributing the decline to reduced sales from two larger distributors [5]. - Following the announcement, Napco's stock price fell from $36.70 per share on January 31, 2024, to $26.93 per share on February 3, 2025, marking a decline of approximately 26.62% in one day [6]. - The company also retracted its long-term 45% EBITDA margin target, indicating uncertainty about achieving this goal by the end of fiscal 2026 [5].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misrepresenting its capital allocation priorities and significantly reducing its quarterly dividend [1][7]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey [1]. - Investors who acquired Organon shares during the class period (October 31, 2024 – April 30, 2025) are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025 [1][3][7]. Group 2: Allegations Against Organon - Organon is accused of concealing material information regarding its capital allocation priorities, particularly in relation to its quarterly dividend [7]. - The company publicly emphasized dividends as a top priority while internally shifting focus towards debt reduction [7]. - Following the acquisition of Dermavant Sciences Ltd., Organon drastically reduced its quarterly dividend by over 90% [7]. Group 3: Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP has over 125 years of legal expertise in securities litigation and aims to protect the rights of investors [4].